Founded in 2013, Health2Sync developed a diabetes management app that integrates blood glucose data, diet, and medication records, attracting 1.48 million users worldwide. The company has partnered with global healthcare giants like Abbott and Sanofi, incorporating the SoloSmart™ smart insulin pen cap into its platform.
In 2023, Health2Sync's Insultrate software received Taiwan FDA approval, becoming the country’s first digital therapeutic. The company plans to expand Insultrate to Japan, Korea, and Australia, while also broadening its focus to chronic disease management, weight control, and GLP-1 medication integration. Additionally, Health2Sync is investing in AI development to enhance patient care and improve medical decision-making efficiency.
We look forward to co-founder and CEO Ed Deng leveraging this funding round to drive Health2Sync's global growth and improve the lives of diabetes and chronic disease patients worldwide. Go Health2Sync!
數位時代新聞報導：智抗糖完成6.6億元C輪募資，緯創資通、和碩等台廠加入投資人行列
